Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

2
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
2
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

469
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
469
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

617
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
617
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

263
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
263
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

549
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
549

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker screen-guided care for preterm birth risk in nulliparous pregnancies: a subgroup analysis of the PRIME randomized controlled trial.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2026
Same author

Preparing for an Aging Africa: Data-Driven Priorities for Economic Research and Policy.

Journal of political economy microeconomics·2026
Same author

Time of Flight Secondary Ion Mass Spectrometry for Characterization of Pt-Coated Porous Transport Layers in PEM Water Electrolyzers.

ACS applied nano materials·2026
Same author

Tele-guided Ultrasound Lung Imaging for Paramedics (TULIP)-An Acceptability Study.

Journal of imaging informatics in medicine·2026
Same author

Validation of cognitive and psychosocial tools in Kenya: findings from the LOSHAK feasibility pilot.

BMC public health·2025
Same author

A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma.

British journal of clinical pharmacology·2025

Related Experiment Video

Updated: Feb 14, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to

Venkatesh Pilla Reddy1, Michael Walker1,2, Pradeep Sharma3

  • 1Modelling and Simulation, Oncology DMPK, IMED Biotech Unit, AstraZeneca, UK.

CPT: Pharmacometrics & Systems Pharmacology
|February 23, 2018
PubMed
Summary

Osimertinib, an EGFR inhibitor, is metabolized by CYP3A4/5. A PBPK model predicted drug-drug interactions, recommending a 160 mg daily dose with strong CYP3A inducers.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.4K

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Metabolism

Background:

  • Osimertinib is a targeted therapy for EGFR-mutated non-small cell lung cancer.
  • Understanding its drug-drug interaction (DDI) profile is crucial for safe and effective use.
  • Osimertinib is metabolized by cytochrome P450 (CYP)3A4/5 and inhibits breast cancer resistance protein (BCRP).

Purpose of the Study:

  • To develop and validate a physiologically based pharmacokinetic (PBPK) model for osimertinib.
  • To predict the impact of DDIs on osimertinib pharmacokinetics.
  • To establish dosing recommendations for osimertinib in combination with other drugs.

Main Methods:

  • Integrated in vitro metabolism, clinical pharmacokinetic, and DDI data.
  • Developed a PBPK model for osimertinib.
  • Validated the PBPK model against observed clinical DDI data with CYP3A inducers (rifampicin, itraconazole) and statins (simvastatin, rosuvastatin).

Main Results:

  • The PBPK model accurately predicted osimertinib's monotherapy concentration profile (within 1.1-fold).
  • The model demonstrated good predictability for DDI ratios (within 1.7-fold) with rifampicin, itraconazole, and simvastatin.
  • No significant DDI was predicted with rosuvastatin.

Conclusions:

  • A 160 mg daily dose of osimertinib is recommended when co-administered with strong CYP3A inducers.
  • PBPK modeling indicates no dose adjustment is necessary with moderate and weak CYP3A inducers.
  • The PBPK model provides a reliable tool for predicting osimertinib DDIs and guiding dosing strategies.